As Biogen, Eli Lilly Fall Short, Roche Intensifies Work on Two Alzheimer's Drugs
Roche is to step up its research efforts on two Alzheimer's drugs, both of which suffered setbacks in tests last year, reflecting its belief in drugs targeting protein plaques found in brains of patients with the disease.
The move follows new evidence presented on Wednesday that rival antibody drugs from Eli Lilly and Biogen, working in a similar way, may produce improvements in people with the memory-robbing condition.
A Roche spokesman said crenezumab would now move into late-stage Phase III development and it also aimed to run fresh clinical trials using higher doses of gantenerumab, after that drug failed in an initial Phase III study.
Help employers find you! Check out all the jobs and post your resume.
The move follows new evidence presented on Wednesday that rival antibody drugs from Eli Lilly and Biogen, working in a similar way, may produce improvements in people with the memory-robbing condition.
A Roche spokesman said crenezumab would now move into late-stage Phase III development and it also aimed to run fresh clinical trials using higher doses of gantenerumab, after that drug failed in an initial Phase III study.
Help employers find you! Check out all the jobs and post your resume.